Table 1.
Patient and graft characteristics
| Variable | Haploidentical N = 89 | Matched related N = 69 | P |
|---|---|---|---|
| Age (years), median (range) | 22 (4–51) | 33 (7–61) | <0.001 |
| Children, no. (%) | 33 (37.1%) | 7 (10.1%) | <0.001 |
| Adult, no. (%) | 56 (62.9%) | 62 (89.9%) | |
| Male/female, no. | 57/32 | 39/30 | 0.337 |
| SAA/VSAA, no. | 69/20 | 58/11 | 0.305 |
| Disease course (months), median (range) | 0.507 | ||
| Interval from SAA diagnosis to SCT | 1.5 (1–4.0) | 1.0 (1–3.0) | |
| Previous transfusion | |||
| Median units of RBC (range) | 7.0 (0–30) | 8.0 (2–34) | 0.115 |
| Median units of PLT (range) | 13.5 (0–90) | 10.0 (2–90) | 0.036 |
| aECOG pre-SCT, median, (range) | 1 (0–3) | 1 (0–2) | 0.568 |
| Donor-patient sex match, no. (%) | 0.042 | ||
| Male-male | 40 (44.9%) | 17 (24.6%) | |
| Male-female | 19 (21.3%) | 15 (21.7%) | |
| Female-male | 19 (21.3%) | 22 (31.9%) | |
| Female-female | 11 (12.4%) | 15 (21.7%) | |
| Donor type, no. (%) | <0.001 | ||
| Sibling | 25 (28.1%) | 69 (100%) | |
| Parent | 57 (64.0%) | – | |
| Child | 5 (5.6%) | – | |
| bOthers | 2 (2.2%) | – | |
| HLA type, no (%) | <0.001 | ||
| 6/6 | 4 (4.5%) | 69 (100%) | |
| 5/6 | 6 (6.7%) | – | |
| 4/6 | 21 (23.6%) | – | |
| 3/6 | 58 (65.2%) | – | |
| ABO matched, no. (%) | 0.414 | ||
| Matched | 49 (55.1%) | 44 (63.8%) | |
| Minor mismatched | 18 (20.2%) | 13 (18.8%) | |
| Major mismatched | 14 (15.7%) | 10 (14.5%) | |
| Different | 8 (9.0%) | 2 (2.9%) | |
| Graft type, no. (%) | <0.001 | ||
| BM + PB | 78 (87.6%) | 43 (63.2%) | |
| BM only | 9 (10.1%) | 3 (4.4%) | |
| PB only | 2 (2.2%) | 22 (32.4%) | |
| Median MNCs, ×10^8/kg (range) | 9.9 (3.4–32.0) | 10.5 (4.6–26.4) | 0.817 |
| Median CD34+ count, ×10^6/kg (range) | 3.6 (0.5–18.8) | 4.5 (1.5–30.2) | 0.001 |
| Median CD3+ count, ×10^8/kg (range) | 1.8 (0.1–6.7) | 2.1 (0.1–7.7) | 0.530 |
| Median CD4+ count, ×10^8/kg (range) | 1.0 (0.1–3.5) | 1.1 (0.1–5.0) | 0.337 |
| Median CD8+ count, ×10^8/kg (range) | 0.7 (0.1–3.0) | 0.8 (0.1–2.7) | 0.147 |
| Median follow-up among alive patients, mo. (range) | 21.4 (7.1–47.6) | 26.0 (7.5–47.6) | 0.258 |
| Neutrophil engraftment, median (range) | 12 (9–20) | 11 (8–19) | 0.151 |
| Platelet engraftment, median (range) | 15 (6–91) | 14 (7–36) | 0.484 |
BM bone marrow, PB peripheral blood, MNC mononuclear cell
*Patient age, previous transfusion of platelet, donor-recipient sex match, graft type, and infused CD34 cells differed significantly between the two groups (P < 0.05). There were no other significances between group differences
aECOG (Eastern Cooperative Oncology Group scale) is used to evaluate patients’ performance status
bOther donor types were from cousins